The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

Eur J Pediatr. 2008 Jun;167(6):695-6. doi: 10.1007/s00431-007-0547-3. Epub 2007 Jun 23.


Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5-10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin--the protein involved in FMF--has a role in activating the proinflammatory cytokine interleukin (IL)-1beta. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antirheumatic Agents / therapeutic use*
  • Colchicine / pharmacology
  • Colchicine / therapeutic use
  • Drug Resistance
  • Familial Mediterranean Fever / drug therapy*
  • Female
  • Gout Suppressants / pharmacology
  • Gout Suppressants / therapeutic use
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*


  • Antirheumatic Agents
  • Gout Suppressants
  • Interleukin 1 Receptor Antagonist Protein
  • Colchicine